Liver Disease Treatment Market to Hit $19,536 million by upcoming Years | GlaxoSmithKline plc, Merck & Co. Inc, Sanofi AG, Pfizer Inc.

The Global Liver Disease Market is projected to reach $19.5 billion by 2022, growing at a CAGR of 11.72% during the forecast period, 2016 – 2022. The antiviral drug segment held major share of the total market in 2015 and is expected to maintain its lead throughout the forecast period. This is attributed to the high incidences of virus infected liver diseases including Hepatitis. However, corticosteroid drug segment registered fastest growing segment during the forecast period.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/388

The report segments the global liver disease market based on treatment type and geography. Based on the treatment type, the market is divided into anti-rejection drugs/immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, anti-viral drugs, immunoglobulins, and corticosteroids. The antiviral drugs segment accumulated the highest revenue in 2014 and is expected to continue its dominance through 2022. Meanwhile, the corticosteroids drug segment is projected to grow at the fastest rate, registering a CAGR of 16.5% during the forecast period.

Key findings of the study:

Corticosteroids drug is projected to be the fastest growing segment, registering a CAGR of 16.49% during the forecast period.
North America is expected to lead the market throughout 2022 and is projected to grow at a CAGR of 11.89%, during 2016 and 2022.
Asia-Pacific is expected to grow with a CAGR of around 12.51%, due to increasing prevalence of liver diseases and increasing R&D investments in this region.

Get detailed COVID-19 impact analysis on the Liver Disease Treatment Market:

https://www.alliedmarketresearch.com/request-for-customization/388?reqfor=covid

Key players in the industry-
Gilead Science Inc.
Bayer AG
AstraZeneca PLC
GlaxoSmithKline plc
Merck & Co. Inc
Sanofi AG
Pfizer Inc.
Bristol-Myers Squibb Company
Novartis AJ
Johnson & Johnson Private Limited.

North America and Europe collectively accounted for more than two-fourth of the total liver disease treatment market in 2015, and are expected to maintain their position throughout the forecast period. This is due to the increasing prevalence of liver diseases, growing geriatric population, and increased awareness about the various liver diseases and their treatment in these regions. In addition, advancement in R&D is anticipated in the development of novel drug therapy for the treatment of liver diseases.

Access Full Report @ https://www.alliedmarketresearch.com/liver-diseases-therapeutics-market

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.